Free Trial

Bausch + Lomb (BLCO) Competitors

Bausch + Lomb logo
$11.27 +0.08 (+0.71%)
Closing price 03:59 PM Eastern
Extended Trading
$11.09 -0.18 (-1.60%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BLCO vs. SOLV, SNN, PEN, STVN, GKOS, NARI, IRTC, INSP, TMDX, and SLNO

Should you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), iRhythm Technologies (IRTC), Inspire Medical Systems (INSP), TransMedics Group (TMDX), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry.

Bausch + Lomb vs.

Bausch + Lomb (NYSE:BLCO) and Solventum (NYSE:SOLV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.

Bausch + Lomb presently has a consensus target price of $15.50, suggesting a potential upside of 37.53%. Solventum has a consensus target price of $80.29, suggesting a potential upside of 10.59%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, equities analysts clearly believe Bausch + Lomb is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch + Lomb
1 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.25
Solventum
1 Sell rating(s)
7 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.10

In the previous week, Solventum had 6 more articles in the media than Bausch + Lomb. MarketBeat recorded 17 mentions for Solventum and 11 mentions for Bausch + Lomb. Solventum's average media sentiment score of 1.37 beat Bausch + Lomb's score of 0.70 indicating that Solventum is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bausch + Lomb
6 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Solventum
11 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch + Lomb$4.83B0.82-$317M-$1.03-10.94
Solventum$8.31B1.51$373.71M$2.1633.61

Solventum has a net margin of 0.00% compared to Bausch + Lomb's net margin of -6.62%. Bausch + Lomb's return on equity of 3.35% beat Solventum's return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch + Lomb-6.62% 3.35% 1.66%
Solventum N/A N/A N/A

11.1% of Bausch + Lomb shares are owned by institutional investors. 0.8% of Bausch + Lomb shares are owned by company insiders. Comparatively, 0.1% of Solventum shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Bausch + Lomb received 39 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 41.00% of users gave Bausch + Lomb an outperform vote while only 7.41% of users gave Solventum an outperform vote.

CompanyUnderperformOutperform
Bausch + LombOutperform Votes
41
41.00%
Underperform Votes
59
59.00%
SolventumOutperform Votes
2
7.41%
Underperform Votes
25
92.59%

Summary

Bausch + Lomb beats Solventum on 9 of the 17 factors compared between the two stocks.

Get Bausch + Lomb News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLCO vs. The Competition

MetricBausch + LombOphthalmic goods IndustryMedical SectorNYSE Exchange
Market Cap$3.98B$10.50B$5.33B$19.30B
Dividend YieldN/A0.96%5.21%3.84%
P/E Ratio-12.3833.9426.7134.53
Price / Sales0.823.10386.1334.83
Price / Cash8.4114.5338.2517.51
Price / Book0.612.586.774.69
Net Income-$317M$224.27M$3.23B$1.02B
7 Day Performance-4.25%3.14%1.80%-1.74%
1 Month Performance-9.73%18.06%11.10%7.50%
1 Year Performance-23.28%-17.97%17.11%4.15%

Bausch + Lomb Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLCO
Bausch + Lomb
4.1301 of 5 stars
$11.27
+0.7%
$15.50
+37.5%
-22.8%$3.98B$4.83B-12.3812,500Gap Up
SOLV
Solventum
2.0076 of 5 stars
$75.81
+2.3%
$80.29
+5.9%
+19.0%$13.12B$8.31B35.1022,000Positive News
Analyst Upgrade
SNN
Smith & Nephew
2.2116 of 5 stars
$29.09
+0.7%
$28.00
-3.7%
+11.0%$12.74B$5.81B13.4720,100News Coverage
PEN
Penumbra
4.7118 of 5 stars
$280.89
+0.1%
$302.40
+7.7%
+35.0%$10.88B$1.24B826.153,900Positive News
STVN
Stevanato Group
1.3372 of 5 stars
€24.64
+2.6%
N/A+24.6%$7.46B$1.12B52.434,650Positive News
GKOS
Glaukos
4.6181 of 5 stars
$95.78
+0.3%
$134.67
+40.6%
-12.5%$5.47B$404.52M-33.37780Positive News
Analyst Revision
NARI
Inari Medical
0.5859 of 5 stars
$79.97
flat
$69.22
-13.4%
N/A$4.68B$493.63M-59.24800
IRTC
iRhythm Technologies
1.2487 of 5 stars
$141.78
+0.6%
$128.55
-9.3%
+52.9%$4.53B$618.59M-38.951,790Positive News
Analyst Forecast
INSP
Inspire Medical Systems
4.67 of 5 stars
$149.86
-1.8%
$211.91
+41.4%
-4.0%$4.42B$840.11M86.62760Positive News
TMDX
TransMedics Group
1.2881 of 5 stars
$122.10
+0.4%
$126.70
+3.8%
-12.4%$4.13B$488.23M129.89210Positive News
Gap Down
SLNO
Soleno Therapeutics
4.8494 of 5 stars
$75.58
+0.8%
$106.78
+41.3%
+65.6%$3.81BN/A-22.7730News Coverage
Positive News

Related Companies and Tools


This page (NYSE:BLCO) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners